CSL Behring begins phase II study of COVID-19 therapy
CSL Behring has enrolled the first patient in its phase clinical II study to assess the safety and efficacy of CSL312 (garadacimab, factor XIIa-inhibitory monoclonal antibody) to treat respiratory distress associated with COVID-19. Read More
Anixa, OntoChem screen SARS-CoV-2 main protease inhibitors
Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors. Read More
Dragonfly, Bristol Myers Squibb to develop immunotherapies
Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple sclerosis and neuroinflammatory targets. Read More
SiO2 increases vial capacity for COVID-19 vaccines
Advanced materials company SiO2 Materials Science has increased the manufacturing capacity of its plastic medical-grade vials to help meet the demand for COVID-19 vaccines. Read More
Affinity finds potent SARS-CoV-2 antibodies
Australian cancer therapeutics company Affinity Biosciences has discovered potent SARS-CoV-2 antibodies with potential therapeutic applications against the novel coronavirus. Read More
Hansa licenses enzyme pretreatment for gene therapy
Hansa Biopharma has entered into an agreement with Sarepta Therapeutics for an exclusive worldwide license to develop and promote imlifidase as a pretreatment for gene therapy treatment of Duchenne muscular dystrophy and limb-girdle muscular dystrophy. Read More
Inimmune gets grant for vaccine technology
Montana-based Inimmune received a $2 million grant from the U.S. National Institute for Allergy and Infectious Diseases to develop novel adjuvant and delivery systems for vaccines. Read More
Sherlock, Binx to develop rapid CRISPR COVID-19 test
Sherlock Biosciences and Binx Health have partnered to create a rapid, point-of-care test for COVID-19 utilizing CRISPR technology. Read More
Luminex rolls out biological test platform to partners
Luminex has delivered the xMap Intelliflex system, a new version of its multiplexed biological test platform, to several life science partners. Read More
New labs being built in Philadelphia due to gene, cell therapy demand
Real estate developer MRA Group is building lab spaces in Philadelphia to meet the region's growing demand for cell and gene therapy. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
